What is Atomoxetine?
Atomoxetine is a selective norepinephrine reuptake inhibitor (SNRI) FDA-approved for treating Attention-Deficit/Hyperactivity Disorder (ADHD) in children (≥6 years), adolescents, and adults. 1
Mechanism of Action
Atomoxetine works by binding to the norepinephrine transporter, blocking norepinephrine reuptake and increasing synaptic norepinephrine levels 2. In the prefrontal cortex specifically, where dopamine transporters are scarce, norepinephrine transporters also regulate dopamine reuptake—therefore atomoxetine increases both norepinephrine and dopamine in prefrontal cortex synapses 2. This mechanism differs fundamentally from stimulant medications, making atomoxetine the first FDA-approved nonstimulant for ADHD treatment 1.
Clinical Role in ADHD Treatment
Atomoxetine represents one of three FDA-approved nonstimulant medications for ADHD (alongside guanfacine and clonidine) 3. It is generally recommended as second-line therapy when stimulants are not suitable, not tolerated, or have been ineffective 2. However, atomoxetine offers specific advantages:
- Non-controlled substance status with negligible abuse potential
- Around-the-clock symptom coverage (unlike short-acting stimulants)
- Particularly useful for patients at risk of substance abuse
- Beneficial for patients with comorbid anxiety or tics 3
Limited evidence supports using atomoxetine as adjunctive therapy combined with stimulants when stimulant monotherapy provides insufficient response 3.
Formulations and Dosing
Available as capsules (10,18,25,40,60,80,100 mg atomoxetine hydrochloride) and oral solution (4 mg/mL) 2. Dosing follows a weight-based approach with maximum recommended dose of 1.4 mg/kg/day or 100 mg/day, whichever is lower 2. The medication can be administered once daily or split into two equal doses (morning and evening) to reduce adverse effects 2.
Critical Safety Warnings
FDA Black Box Warning: Suicidal Ideation
Atomoxetine carries an FDA black box warning for increased suicidal thoughts in children and adolescents 3. Analysis of 12 placebo-controlled trials showed 4 out of every 1,000 patients developed suicidal thoughts (though no completed suicides occurred) 2. Close monitoring is mandatory, especially during the first few months of treatment and during dose adjustments 1.
Cardiovascular Effects
Atomoxetine may cause increased heart rate and blood pressure 3. Before initiating treatment, obtain:
- Personal and family cardiac history (sudden death, cardiovascular symptoms, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, long QT syndrome)
- ECG if risk factors present, with possible cardiology referral if abnormal 3
Monitor blood pressure and heart rate regularly during treatment 1.
Hepatotoxicity
Extremely rare cases of severe liver injury have occurred, including one case requiring liver transplant 4. Discontinue immediately if patients develop jaundice, dark urine, right upper abdominal pain, or unexplained flu-like symptoms 1.
Common Adverse Effects
Most frequent side effects include 3, 2:
- Nausea, vomiting, abdominal pain
- Decreased appetite
- Somnolence and fatigue
- Initial gastrointestinal symptoms (particularly with rapid dose escalation)
Growth delays may occur in the first 1-2 years of treatment (especially in taller/heavier children), but measurements typically return to expected trajectories after 2-3 years 3.
Important Drug Interactions
Atomoxetine is primarily metabolized via CYP2D6 2. Approximately 7% of the population are poor CYP2D6 metabolizers, resulting in significantly higher plasma levels and longer half-lives, which increases adverse effect risk 2. Selective serotonin reuptake inhibitors (SSRIs) that inhibit CYP2D6 can substantially elevate atomoxetine levels 2.
Contraindications
Do not use atomoxetine if patient:
- Is taking or has taken MAOIs within past 14 days
- Has narrow-angle glaucoma
- Has pheochromocytoma
- Has known allergy to atomoxetine 1
Efficacy Considerations
Atomoxetine demonstrates medium effect sizes compared to placebo—smaller than stimulant medications 2. Head-to-head trials confirm stimulants are more effective 2. Additionally, treatment effects typically require 6-12 weeks to manifest (versus rapid onset with stimulants) 2. This delayed onset is a critical counseling point for patients and families.
Special Populations
Atomoxetine has not received sufficient rigorous study in preschool-aged children (4-5 years) to be recommended for this age group 3. For children ≥6 years, adolescents, and adults, atomoxetine should be part of a comprehensive ADHD treatment program including behavioral interventions 1.